On January 11, 2026, during J.P. Morgan Healthcare Week, American Healthcare Executive Association was proud to partner with bioSeedin to co-host the BIOseedin Winter Innovation Partnering Summit in San Francisco.

The summit brought together global pharma executives, biotech founders, BD leaders, and investors to spotlight high-potential innovation assets and advance cross-border deal-making conversations at one of the most active weeks in the global healthcare calendar.

We were honored to collaborate with and be supported by outstanding partners and sponsors, including Eli Lilly and Company, Roche, ACROBiosystems, and Fangda Partners, whose engagement helped make this platform possible.

Key themes that stood out:

🔹 Clinical signal quality over novelty· Clean clinical data, validated MoA, and thoughtful patient selection emerged as decisive differentiators — particularly across bispecifics, ADCs, and immunology pipelines.

🔹 De-risked and peripheral innovation gaining traction

· Assets outside hot-core indications, supported by strong translational rationale, are increasingly drawing strategic interest from pharma and investors.

🔹 Evolving deal structures

· Earlier-stage partnerships, option-based collaborations, and staged risk-sharing models are reshaping platform and multi-asset pipeline strategies.

🔹 Cardio–renal–metabolic momentum building

· Beyond GLP-1s, renewed BD attention is forming around novel mechanisms, long-acting modalities, and disease-modifying approaches.

At AHEA, we remain committed to fostering executive exchange, cross-border collaboration, and strategic partnership opportunities that accelerate life sciences innovation globally.

A sincere thank you to bioSeedin, our partners, speakers, and participants for making this summit a success. We look forward to continuing the conversations sparked in San Francisco.